[go: up one dir, main page]

PE20010854A1 - USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS - Google Patents

USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS

Info

Publication number
PE20010854A1
PE20010854A1 PE2000001131A PE0011312000A PE20010854A1 PE 20010854 A1 PE20010854 A1 PE 20010854A1 PE 2000001131 A PE2000001131 A PE 2000001131A PE 0011312000 A PE0011312000 A PE 0011312000A PE 20010854 A1 PE20010854 A1 PE 20010854A1
Authority
PE
Peru
Prior art keywords
derivatives
antagonists
substituted pyrimidine
carbocyclic
alkyl
Prior art date
Application number
PE2000001131A
Other languages
Spanish (es)
Inventor
Willian Martin Owton
Kirk Willis Johnson
Samantha Jayne Ambler
Darrell Stephen Coleman
John Goldsworthy
Ann Elizabeth Kingston
Jeffrey Michael Schkeryantz
Darryle Darwin Schoepp
Stephen Richard Baker
Mohammad Sadegh Zia-Ebrahimi
Michael Scott Vannieuwenhze
Jian Eric Hong
Gunnar Erik Jagdmann Jr
Robert James Foglesong
Barry Peter Clark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010854A1 publication Critical patent/PE20010854A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL USO DE DERIVADOS DE PIRIMIDINA 4-SUSTITUIDAS DE FORMULA I, DONDE X1 ES O, NH; L ES UN ENLACE, ALQUILENO C1-C6 OPCIONALMENTE SUSTITUIDO CON F, OH, ALCOXI C1-C4, OXO; R1 ES CARBOCICLICO, HETEROCICLICO; R2 ES H, HALOGENO, CARBOXILO, CIANO, SCH2N, X2-R5; X2 ES UN ENLACE, O, S, SO, SO2, NH; R5 ES ALQUILO C1-C8, CICLOALQUILO C3-C10, HALOALQUILO C1-C6, HIDROXIALQUILO C1-C6, ENTRE OTROS; R3 Y R4 SON ALQUILO C1-C4 O JUNTO A C FORMAN UN ANILLO CARBOCICLICO, HETEROCICLICO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION, A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE GLUTAMATO mGluR1 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DOLOR, MIGRANAREFERS TO THE USE OF 4-SUBSTITUTED PYRIMIDINE DERIVATIVES OF FORMULA I, WHERE X1 IS O, NH; L IS A BOND, C1-C6 ALKYLENE OPTIONALLY SUBSTITUTED WITH F, OH, C1-C4 ALCOXY, OXO; R1 IS CARBOCYCLIC, HETEROCYCLIC; R2 IS H, HALOGEN, CARBOXYL, CYANE, SCH2N, X2-R5; X2 IS A LINK, O, S, SO, SO2, NH; R5 IS C1-C8 ALKYL, C3-C10 CYCLOALKYL, C1-C6 HALOALKYL, C1-C6 HYDROXYALKYL, AMONG OTHERS; R3 AND R4 ARE C1-C4 ALKYL OR TOGETHER WITH C, THEY FORM A CARBOCYCLIC, HETEROCICLIC RING. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION, TO INTERMEDIATE COMPOUNDS. COMPOUND I IS AN ANTAGONIST OF THE GLUTAMATE RECEPTOR mGluR1 AND MAY BE USEFUL FOR THE TREATMENT OF PAIN, MIGRAN

PE2000001131A 1999-11-01 2000-10-20 USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS PE20010854A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16290099P 1999-11-01 1999-11-01

Publications (1)

Publication Number Publication Date
PE20010854A1 true PE20010854A1 (en) 2001-08-28

Family

ID=22587589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001131A PE20010854A1 (en) 1999-11-01 2000-10-20 USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS

Country Status (7)

Country Link
EP (1) EP1230225A2 (en)
AR (1) AR026275A1 (en)
AU (1) AU1071301A (en)
CO (1) CO5261605A1 (en)
PE (1) PE20010854A1 (en)
SV (1) SV2002000205A (en)
WO (1) WO2001032632A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7423044B2 (en) 2002-09-05 2008-09-09 Wyeth Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
AR044743A1 (en) * 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd HERBICIDE, METHOD OF USE, DERIVED FROM REPLACED TIENOPIRIMIDINE, INTERMEDIATE COMPOUNDS, AND PROCEDURES USED TO PRODUCE THEM,
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
CA2514473C (en) * 2002-11-22 2008-05-27 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co Nitrogen-containing heterocyclic compounds and medicinal use thereof
CN1774250A (en) 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 (6-(phenoxy)-pyrido[3,4-D]pyrimidin-2-yl)-amine derivatives as P38 kinase inhibitors for the treatment of inflammatory diseases such as rheumatoid arthritis
CA2522522A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005016925A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Azaquinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
PE20060526A1 (en) * 2004-06-15 2006-07-13 Schering Corp TRICYCLE COMPOUNDS AS ANTAGONISTS OF MGLUR1
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
ATE435214T1 (en) * 2004-09-02 2009-07-15 Vertex Pharma CHINAZOLINES SUITABLE AS ION CHANNEL MODULATORS
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
JP2009507849A (en) * 2005-09-09 2009-02-26 ブリストル−マイヤーズ スクイブ カンパニー Acyclic IKur inhibitor
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1963336A1 (en) * 2005-12-20 2008-09-03 Richter Gedeon NYRT New compounds
HUP0501170A2 (en) * 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
US20100022521A1 (en) * 2005-12-20 2010-01-28 Hansa Metallwerke Ag Compounds
HUP0501168A3 (en) * 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
JP2009521479A (en) 2005-12-21 2009-06-04 アボット・ラボラトリーズ Antiviral compounds
CA2633760A1 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
DE102006012251A1 (en) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
ES2610508T3 (en) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Methods to treat Down syndrome, fragile X syndrome and autism
CA2672737A1 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
KR20100052507A (en) 2007-08-02 2010-05-19 레코르다티 아일랜드 리미티드 Novel heterocyclic compounds as mglu5 antagonists
HRP20110278T1 (en) 2007-09-14 2011-05-31 Ortho-Mcneil-Janssen Pharmaceuticals 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4']bipyridinyl-2'-ones
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
ME01461B (en) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
JP5539351B2 (en) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them
JP5547194B2 (en) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US20110257208A1 (en) * 2008-11-19 2011-10-20 Matthew Duncton Compounds useful as faah modulators and uses thereof
CN102232074B (en) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010077613A1 (en) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
US20100317630A1 (en) 2009-02-04 2010-12-16 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
CN102439008B (en) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-Triazolo[4,3-A]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20120028931A1 (en) 2009-09-14 2012-02-02 Recordati Ireland Limited Heterocyclic m-glu5 antagonists
WO2011106276A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
JP2013529673A (en) 2010-07-09 2013-07-22 レコルダーティ アイルランド リミテッド Novel spiroheterocyclic compounds as MGLU5 antagonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
MX2013003913A (en) 2010-10-08 2013-09-26 Abbvie Inc FURO[3,2-d]PYRIMIDINE COMPOUNDS.
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (en) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of the MGLUR2 receptor
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
TWI499591B (en) 2013-01-11 2015-09-11 Lilly Co Eli Bicyclic pyrimidine compounds
TW201520219A (en) * 2013-03-12 2015-06-01 Lilly Co Eli Imidazo pyridine compounds
TW201500356A (en) * 2013-04-12 2015-01-01 Lilly Co Eli Dihydropyrido pyrimidine compounds
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
MX368491B (en) 2013-07-11 2019-10-04 Acea Biosciences Inc Pyrimidine derivatives as kinase inhibitors.
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP3096790B1 (en) 2014-01-21 2019-07-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20200036063A (en) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN108290855A (en) 2015-07-01 2018-07-17 西北大学 Substituted quinazoline compound and its purposes for adjusting glucocerebrosidase activity
DK3325490T3 (en) 2015-07-23 2020-02-03 Takeda Pharmaceuticals Co 1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDINE-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS
KR20180067584A (en) 2015-10-09 2018-06-20 아세아 테라퓨틱스 인코포레이티드 PHARMACEUTICALS, PHYSICAL FORM AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS AND METHODS FOR THEIR PREPARATION
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JP2020516682A (en) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase, and methods of making the same
CN115605457B (en) * 2021-04-26 2025-03-18 三菱瓦斯化学株式会社 Compound and method for producing the same
WO2025188952A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
DE19904710A1 (en) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical compositions containing them
SE9903290D0 (en) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
CO5261605A1 (en) 2003-03-31
WO2001032632A2 (en) 2001-05-10
AU1071301A (en) 2001-05-14
SV2002000205A (en) 2002-06-07
EP1230225A2 (en) 2002-08-14
WO2001032632A3 (en) 2001-11-08
AR026275A1 (en) 2003-02-05

Similar Documents

Publication Publication Date Title
PE20010854A1 (en) USE OF SUBSTITUTED PYRIMIDINE 4 DERIVATIVES AS ANTAGONISTS OF GLUTAMATE mGluR1 RECEPTORS
PE20040935A1 (en) 2-QUINAZOLINE SUBSTITUTE-4-ILAMINE ANALOGS AS MODULATORS OF CAPSAICIN RECEPTORS
PE20021072A1 (en) DERIVATIVES OF DIHYDRO-BENZO (b) (1,4) -DIAZEPIN-2-ONA AS ANTAGONISTS I OF mGLUR2
PE20011030A1 (en) PHARMACEUTICAL COMBINATIONS INCLUDING TEGASEROD AND OMEPRAZOLE
PE20010039A1 (en) CARBAMIC ACID ESTER DERIVATIVES AS AGONISTS AND / OR ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
PE20010930A1 (en) BIPHENYL SULPHONAMIDES AS ANTAGONISTS OF DUAL ANGIOTENSIN ENDOTHELIN RECEPTORS
PE20010681A1 (en) BENZODIAZEPINE DERIVATIVES AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
PE20011035A1 (en) CYCLIC UREAS SUBSTITUTED AS ANTAGONISTS OF NEUROQUININ RECEPTORS
ES2052675T3 (en) 3- (4-PIPERAZINIL-SUBSTITUTED IN 1) BUTIL) -4-THIAZOLIDINONAS, A PROCEDURE FOR ITS PREPARATION AND USE AS MEDICINES.
PE20010759A1 (en) BENZODIAZEPINE DERIVATIVES AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
PE20020753A1 (en) HETEROAROMATICS FUSED AS GLUCOKINASE ACTIVATORS
AR004516A1 (en) DERIVATIVES OF PYRIMIDINE, ITS USE, PROCEDURES TO PREPARE THEM AND MEDICINES THAT CONTAIN THEM
AR018917A1 (en) ADENOSINE DERIVATIVE COMPOUNDS THAT ARE AGONISTS IN THE ADENOSINE A1 RECEIVER, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PE20030759A1 (en) USE OF BENZOTHIAZOLES UREAS
ES2108700T3 (en) DIAZABICICLONOLYL DERIVATIVES AS ANTAGONISTS OF THE 5-HT3 RECEPTOR.
PE20050896A1 (en) QUINOLINE INTERMEDIARIES AS INHIBITORS OF TIROSINE KINASES OF RECEPTORS AND THE SYNTHESIS OF THE SAME
ATE271039T1 (en) UREA DERIVATIVES EFFECTIVE AS MUSCARINE RECEPTOR ANTAGONISTS
PE20050429A1 (en) DERIVATIVES OF 2-PHENYLAMINE-4-AMINO-PYRIMIDINE AS KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PREPARATION PROCESS
PE20010629A1 (en) TRIAZOLPYRIDINAMINE DERIVATIVES AS ADENOSINE RECEPTOR LINKS
PE20010641A1 (en) PIPERAZINE DERIVATIVES AS ANTAGONISTS OF THE SEROTONIN 5-HT1B RECEPTOR
PE20050465A1 (en) QUINUCLIDINE DERIVED COMPOUNDS AS ANTAGONISTS OF THE MUSCARINE M3 RECEPTOR
PE20040772A1 (en) COMPOSITION AND ANTIVIRAL ACTIVITY OF PIPERAZINE DERIVATIVES AZAINDOLOXOACETICS
PE20021013A1 (en) DIHYDROPYRIMIDINES-5-CYANE SUBSTITUTED AS ANTIPROLIFERATIVE AGENTS
EA200300619A1 (en) SEROTONINERGIC MEANS
PE20020258A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE AS ANTAGONISTS OF THE NEUROQUININ 1 (NK-1) RECEPTOR

Legal Events

Date Code Title Description
FD Application declared void or lapsed